Skip to main content

Table 1 Baseline characteristics

From: Comparison of the outcomes between sorafenib and lenvatinib as the first-line systemic treatment for HBV-associated hepatocellular carcinoma: a propensity score matching analysis

 

Before PSM

After PSM

Lenvatinib (n = 44)

Sorafenib (n = 162)

SMD

Lenvatinib (n = 44)

Sorafenib (n = 88)

SMD

Male gender, N (%)

40 (90.9%)

144 (88.9%)

 − 0.056

40 (90.9%)

80 (90.9%)

0.000

Age (yr), median (IQR)

58 (51.5–64.8)

59 (53.8–65.0)

 − 0.055

58 (51.5–64.8)

58 (52.3–64.8)

 − 0.016

ALT (IU/L), median (IQR)

41.5 (25.0–66.0)

34 (25.0–54.0)

0.198

41.5 (25.0–66.0)

37.5 (26.0–65.0)

0.050

AST (IU/L), median (IQR)

52.0 (31.5–89.8)

49 (34.0–78.0)

0.123

52.0 (31.5–89.8)

50.5 (35.3–84.0)

0.029

Total bilirubin (mg/dL), median (IQR)

1.00 (0.60–1.73)

1.00 (0.60–1.30)

0.220

1.00 (0.60–1.73)

1.10 (0.70–1.48)

0.136

Albumin (g/dL), median (IQR)

3.8 (3.2–4.1)

3.7 (3.3–4.1)

 − 0.044

3.8 (3.2–4.1)

3.7 (3.1–4.0)

0.099

PT (INR), median (IQR)

1.16 (1.06–1.24)

1.10 (1.03–1.18)

0.256

1.16 (1.06–1.24)

1.10 (1.02–1.20)

0.199

PIVKA (mAU/mL), median (IQR)

1160.0 (115.0–4938.0)

870.5 (110.8–5338.8)

 − 0.041

1160.0 (115.0–4938.0)

1174.0 (116.3–4346.8)

0.010

AFP (ng/mL), median (IQR)

132.6 (14.6–5980.0)

427.7 (10.2–4442.5)

 − 0.270

132.6 (14.6–5980.0)

86.8 (6.9–3600.0)

 − 0.069

Child–Pugh class, N (%)

  

0.277

  

0.059

A

29 (65.9%)

129 (79.6%)

 

29 (65.9%)

63 (71.6%)

 

B

13 (29.5%)

27 (16.7%)

 

13 (29.5%)

19 (21.6%)

 

C

2 (4.5%)

6 (3.7%)

 

2 (4.5%)

6 (6.8%)

 

ECOG, N (%)

  

 − 0.307

  

 − 0.205

0

23 (71.9%)

99 (61.1%)

 

23 (71.9%)

48 (62.3%)

 

1

9 (28.1%)

57 (35.2%)

 

9 (28.1%)

29 (37.7%)

 

BCLC stage, N (%)

  

0.135

  

 − 0.034

B

4 (9.1%)

17 (10.5%)

 

4 (9.1%)

8 (9.1%)

 

C

39 (88.6%)

142 (87.7%)

 

39 (88.6%)

77 (87.5%)

 

D

1 (2.3%)

3 (1.9%)

 

1 (2.3%)

3 (3.4%)

 

Tumor size (mm), median (IQR)

76.5 (40.8–127.5)

58.5 (33.0–124.8)

0.145

76.5 (40.8–127.5)

63.0 (33.0–140.5)

0.062

Extrahepatic metastasis, N (%)

  

0.042

  

0.075

Yes

31 (70.5%)

111 (68.5%)

 

31 (70.5%)

59 (67.0%)

 

No

13 (29.5%)

51 (31.5%)

 

13 (29.5%)

29 (33.0%)

 

Portal vein thrombosis, N (%)

  

0.120

  

0.046

Yes

20 (45.5%)

65 (40.1%)

 

20 (45.5%)

37 (42.0%)

 

No

24 (54.5%)

97 (59.9%)

 

24 (54.5%)

51 (58.0%)

 

Biliary invasion, N (%)

  

0.102

  

0.003

Yes

4 (9.1%)

10 (6.2%)

 

4 (9.1%)

9 (10.2%)

 

No

40 (90.9%)

152 (93.8%)

 

40 (90.9%)

79 (89.8%)

 

Previous anti-HCC treatment, N (%)

  

 − 0.109

  

 − 0.056

Yes

35 (79.5%)

136 (84.0%)

 

35 (79.5%)

72 (81.8%)

 

No

9 (20.5%)

26 (16.0%)

 

9 (20.5%)

16 (18.2%)

 

Subsequent anti-HCC treatment, N (%)

  

 − 0.536

   

Yes

15 (34.1%)

92 (56.8%)

 

15 (34.1%)

46 (52.3%)

 

No

30 (65.9%)

70 (43.2%)

 

29 (65.9%)

42 (47.7%)

 

Antiviral treatment, N (%)

  

0.121

  

0.107

Yes

35 (79.5%)

122 (75.3%)

 

35 (79.5%)

67 (76.1%)

 

No

8 (18.2%)

37 (22.8%)

 

8 (18.2%)

20 (22.7%)

 

Viral status

  

 − 0.083

  

 − 0.067

Immune tolerant phase

0 (0.0%)

0 (0.0%)

 

0 (0.0%)

0 (0.0%)

 

HBeAg +, immune active phase

0 (0.0%)

6 (3.7%)

 

0 (0.0%)

3 (3.4%)

 

Immune inactive phase

35 (79.5%)

118 (72.8%)

 

35 (79.5%)

63 (71.6%)

 

HBeAg−, immune active phase

6 (13.6%)

12 (7.4%)

 

6 (13.6%)

8 (9.1%)

 

HBsAg loss phase

2 (4.5%)

17 (10.5%)

 

2 (4.5%)

8 (9.1%)

 
  1. Data are presented as number (%) or median (interquartile range)
  2. PSM, propensity score matching; SMD, standardized mean difference; ALT, alanine aminotransferase; AST, aspartate aminotransferase; PT, prothrombin time; PIVKA, protein induced by vitamin K absence or antagonists-II; AFP, alpha-fetoprotein; ECOG, Eastern Cooperative Oncology Group; BCLC, Barcelona Clinic Liver Cancer; IQR, inter-quartile range; INR, international normalized ratio
Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us